Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,606.49
(
-0.27%
)
US TECH 100
23,764.40
(
-0.13%
)
Dow Jones
46,021.43
(
-0.44%
)
Brent Oil
104.99
(
0.54%
)
Bitcoin
70,247.99
(
0.50%
)
News Focus
News Focus

Replies to post #930 on Israel-Medical-Healthcare

Replies to #930 on Israel-Medical-Healthcare
icon url

genisi

02/25/08 4:45 AM

#931 RE: DewDiligence #930

#msg-27079842
icon url

genisi

02/28/08 11:28 AM

#934 RE: DewDiligence #930

Kamada's (and GTCB's) competitor (I think I've mentioned them somewhere else like here #msg-25991026) Arriva Pharmaceuticals moves forward to Phase IIb development of lead inhaled protein rAAT replacement therapy for hereditary emphysema.

http://www.earthtimes.org/articles/show/arriva-pharmaceuticals-moves-forward-to-phase-2b-development-of-lead,296031.shtml